摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯丙烷-1-磺酰胺 | 35578-28-0

中文名称
3-氯丙烷-1-磺酰胺
中文别名
——
英文名称
3-chloro-propane-1-sulfonic acid amide
英文别名
3-chloropropanesulfonamide;3-Chloropropane-1-sulfonamide
3-氯丙烷-1-磺酰胺化学式
CAS
35578-28-0
化学式
C3H8ClNO2S
mdl
MFCD12107254
分子量
157.621
InChiKey
QMSSNRWVQWLVHG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    63 °C
  • 沸点:
    297.8±42.0 °C(Predicted)
  • 密度:
    1.380±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    8
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    68.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2935009090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302

SDS

SDS:313ef7f1e564d940903bcbb8000f3233
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloropropane-1-sulfonamide
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloropropane-1-sulfonamide
CAS number: 35578-28-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H8ClNO2S
Molecular weight: 157.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯丙烷-1-磺酰胺sodium ethanolate 作用下, 以 乙醇 为溶剂, 反应 9.0h, 以18%的产率得到异噻唑烷 1,1-二氧化物
    参考文献:
    名称:
    缺电子烯烃配体通过镍催化交叉偶联生成季碳
    摘要:
    已开发出镍催化的 Negishi 与 1,1-二取代苯乙烯基氮丙啶的交叉偶联。该方法通过提供季碳的具有挑战性的还原消除来提供有价值的 β-取代苯乙胺。一种新型缺电子烯烃配体 Fro-DO 被证明对于通过 β-H 消除实现 CC 键形成的高速率和化学选择性至关重要。该配体易于获取、稳定,并为反应发现和优化提供了模块化框架。我们预计这些属性,再加上配体赋予金属不同的电子特性,将支持使用既定配体以前不可能实现的新转化的发明。
    DOI:
    10.1021/jacs.5b02503
  • 作为产物:
    描述:
    丙基磺酰胺 在 sodium persulfate 、 copper dichloride 作用下, 以 为溶剂, 反应 5.0h, 以55%的产率得到3-氯丙烷-1-磺酰胺
    参考文献:
    名称:
    Rearrangement of sulfonamidyl radicals with hydrogen migration
    摘要:
    DOI:
    10.1007/bf00954818
点击查看最新优质反应信息

文献信息

  • Benzoxazepinones and their use as squalene synthase inhibitors
    申请人:——
    公开号:US20030078251A1
    公开(公告)日:2003-04-24
    There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.
    披露了一种由公式[I]表示的化合物: 1 其中R 1 是可选地取代的1-羧乙基,可选地取代的烷基亚磺酰基,可选地取代的(羧基环烷基)-烷基,—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基,X 2 和X 3 是键,—O—,—S—,Ar是二价芳香族等),R 2 是可选地由酰氧基和/或羟基取代的烷基,R 3 是烷基,W是卤素原子等,或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性,用于预防或治疗高脂血症。
  • [EN] MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS<br/>[FR] COMPOSÉS MACROCYCLIQUES POUR L'INHIBITION D'INHIBITEURS DE L'APOPTOSE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2014074658A1
    公开(公告)日:2014-05-15
    There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    这里公开了调节凋亡抑制剂(IAPs)活性的化合物,包含所述化合物的药物组合物以及使用本发明的化合物治疗增殖性疾病和凋亡失调疾病的方法,例如癌症。
  • MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS
    申请人:Ensemble Therapeutics Corp.
    公开号:US20140135270A1
    公开(公告)日:2014-05-15
    There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    这里公开了调节凋亡抑制剂(IAPs)活性的化合物,包含所述化合物的药物组合物以及使用本发明的化合物治疗增殖性疾病和凋亡失调疾病的方法,例如癌症。
  • [EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012168350A1
    公开(公告)日:2012-12-13
    The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    本发明涉及式(I)的化合物,其中R1至R4的定义如描述和权利要求中所述。式(I)的化合物可以用作药物。
  • Hepatitis C virus inhibitors
    申请人:Hewawasam Piyasena
    公开号:US20070010455A1
    公开(公告)日:2007-01-11
    The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    本公开涉及三肽化合物、组合物和治疗丙型肝炎病毒(HCV)感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
查看更多